AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17657475 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with decompression and various spondylodeses (n=13)
Number of subjects: 19
Study 17657475 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (n=6)
Number of subjects: 19
Study 15870625 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (21 g x d(-1))
Number of subjects: 0
Study 15870625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12215281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) for 6 courses
Number of subjects: 60
Study 12215281 — intervention group
Group type: COMPARATOR
Intervention: Usual drugs used in the clinic for 60 days
Number of subjects: 60
Study 11776765 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (100 mg, d 1-5) and 5-fluorouracil (500 mg, d 1-5) plus radiotherapy
Number of subjects: 80
Study 11776765 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 80
Study 8574715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 209
Study 8574715 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefuroxime
Number of subjects: 209
Study 8574715 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime protocol
Number of subjects: 209
Study 8574715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin protocol
Number of subjects: 209
Study 2186951 — intervention group
Group type: COMPARATOR
Intervention: arbaprostil 10 micrograms
Number of subjects: 658
Study 2186951 — intervention group
Group type: COMPARATOR
Intervention: arbaprostil 25 micrograms
Number of subjects: 658
Study 2186951 — intervention group
Group type: COMPARATOR
Intervention: arbaprostil 50 micrograms
Number of subjects: 658
Study 531541 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (daily dosage)
Number of subjects: 39
Study 531541 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (alternate-day regimen)
Number of subjects: 39
Study 531541 — intervention group
Group type: COMPARATOR
Intervention: Observation without therapy (Control)
Number of subjects: 39
Study 31812890 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 300 mg twice daily
Number of subjects: 207
Study 31812890 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 207
Study 28528354 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 109
Study 28528354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Resistance Training (FRT)
Number of subjects: 109
Study 28528354 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 109
Study 26389945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy intake
Number of subjects: 600
Study 26389945 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat intake
Number of subjects: 600
Study 26389945 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish and shellfish intake
Number of subjects: 600
Study 26389945 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg intake
Number of subjects: 600
Study 24353023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER tablets (50, 100, 150, 200, or 250 mg)
Number of subjects: 0
Study 24353023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER tablets (250 mg) administered every 12 hours (five doses)
Number of subjects: 0
Study 24353023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER tablets (250 mg) with a high-fat meal
Number of subjects: 0
Study 24353023 — intervention group
Group type: COMPARATOR
Intervention: Tapentadol ER tablets (single dose)
Number of subjects: 0
Study 21464293 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant leptin (metreleptin) in replacement doses over 36 weeks
Number of subjects: 0
Study 21464293 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant leptin (metreleptin)
Number of subjects: 0
Study 21464293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19011727 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (calisthenics, body balance training, muscle power training, walking ability training) 3 days/week for 5 months
Number of subjects: 68
Study 19011727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 68
Study 17084196 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniotomy and early hematoma evacuation
Number of subjects: 108
Study 17084196 — intervention group
Group type: COMPARATOR
Intervention: Best medical management (control)
Number of subjects: 108
Study 14702269 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued perphenazine treatment
Number of subjects: 37
Study 14702269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 11579988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 16
Study 11579988 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy (E)
Number of subjects: 16
Study 9360528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (56 h of total caloric deprivation)
Number of subjects: 8
Study 9360528 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) infusions at a dose of 34-46 mg HC/24 h
Number of subjects: 8
Study 9360528 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 8
Study 9360528 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC) infusions
Number of subjects: 8
Study 8432442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 20 mg daily
Number of subjects: 205
Study 8432442 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 40 mg daily (tapering to 10 or 20 mg)
Number of subjects: 205
Study 3665384 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe-pump system
Number of subjects: 30
Study 3665384 — intervention group
Group type: COMPARATOR
Intervention: Minibottle system
Number of subjects: 30
Study 30222050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training based on motor imagery (MI) and action observation (AO)
Number of subjects: 28
Study 30222050 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic surgical skill group (short 2-day laparoscopic course)
Number of subjects: 28
Study 30222050 — intervention group
Group type: COMPARATOR
Intervention: Control group (neutral activity)
Number of subjects: 28
Study 27022118 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily; n = 172)
Number of subjects: 343
Study 27022118 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin AUC 5 to 6; n = 171)
Number of subjects: 343
Study 24526744 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops (twice daily for 3 days)
Number of subjects: 286
Study 24526744 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 0.3% eye drops (every 2 h for 2 days, then four times daily for 5 days)
Number of subjects: 286
Study 24526744 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops
Number of subjects: 286
Study 24526744 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 0.3% eye drops
Number of subjects: 286
Study 22285891 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice condition (n=44)
Number of subjects: 84
Study 22285891 — intervention group
Group type: COMPARATOR
Intervention: No-choice condition (n=40)
Number of subjects: 84
Study 19783377 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV chemotherapy plus radiation therapy (PCV + RT)
Number of subjects: 0
Study 19783377 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 0
Study 19783377 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV + RT
Number of subjects: 0
Study 18297481 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive exercise routine
Number of subjects: 45
Study 18297481 — intervention group
Group type: COMPARATOR
Intervention: Supervised walking
Number of subjects: 45
Study 18297481 — intervention group
Group type: COMPARATOR
Intervention: Social conversation
Number of subjects: 45
Study 15211599 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP+CPT‐11 (CPT‐P) arm
Number of subjects: 100
Study 15211599 — intervention group
Group type: COMPARATOR
Intervention: CDDP+VDS (VDS‐P) arm
Number of subjects: 100
Study 15211599 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐P arm
Number of subjects: 100
Study 15211599 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐P arm with identical second-line radiotherapy
Number of subjects: 100
Study 11145793 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 632
Study 11145793 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 632
Study 11145793 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 632
Study 9848045 — intervention group
Group type: EXPERIMENTAL
Intervention: Acticoat silver-coated dressing
Number of subjects: 30
Study 9848045 — intervention group
Group type: COMPARATOR
Intervention: 0.5% silver nitrate solution
Number of subjects: 30
Study 7924731 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice daily)
Number of subjects: 15
Study 7924731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2769353 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral backward perturbations
Number of subjects: 0
Study 2769353 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral forward perturbations
Number of subjects: 0
Study 2769353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral perturbations in one direction
Number of subjects: 0
Study 2769353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral perturbations in opposite directions
Number of subjects: 0
Study 2769353 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral displacement
Number of subjects: 0
Study 2769353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral displacements
Number of subjects: 0
Study 2769353 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocnemius muscle activation
Number of subjects: 0
Study 2769353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibialis anterior muscle activation
Number of subjects: 0
Study 402186 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HPO)
Number of subjects: 233
Study 402186 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 233
Study 402186 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended fields (HPO)
Number of subjects: 233
Study 402186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy (HPO)
Number of subjects: 233
Study 31222789 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized electronic messages four times/week for 6 months postpartum
Number of subjects: 0
Study 31222789 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized electronic messages with option for nurse contact for 6 months postpartum
Number of subjects: 0
Study 31222789 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 0
Study 29150046 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 50
Study 26063693 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with pork (DASH-P)
Number of subjects: 19
Study 26063693 — intervention group
Group type: COMPARATOR
Intervention: DASH diet with chicken and fish (DASH-CF)
Number of subjects: 19
Study 26063693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DASH-P and DASH-CF
Number of subjects: 19
Study 23443788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity ultrasound treatment for 30 min daily for 3 consecutive days
Number of subjects: 122
Study 23443788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no particular treatments)
Number of subjects: 122
Study 22411387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral powder supplement enriched with eicosapentaenoic acid (1.5 g)
Number of subjects: 61
Study 22411387 — intervention group
Group type: COMPARATOR
Intervention: Standard liquid supplement
Number of subjects: 61
Study 19540010 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal helmet laws
Number of subjects: 0
Study 19540010 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory rider education programs
Number of subjects: 0
Study 19540010 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed limits on rural interstates
Number of subjects: 0
Study 16953857 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Visiting Group (HVG) - received eight home visits with education and support for parenting, breastfeeding, and child development.
Number of subjects: 152
Study 16953857 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - received telephone contact at two months and a home visit at six months, no education or support provided.
Number of subjects: 152
Study 16953857 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HVG and CG)
Number of subjects: 152
Study 16953857 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention rates
Number of subjects: 152
Study 15208597 — intervention group
Group type: EXPERIMENTAL
Intervention: Amb a 1 linked to immunostimulatory DNA sequence (AIC)
Number of subjects: 19
Study 15208597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11258638 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at 90% of vVO2max
Number of subjects: 10
Study 11258638 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at 100% of vVO2max
Number of subjects: 10
Study 11258638 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at 120% of vVO2max
Number of subjects: 10
Study 11258638 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at 140% of vVO2max
Number of subjects: 10
Study 11258638 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity expressed as %MSR for tlim90 and tlim100
Number of subjects: 10
Study 11258638 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity expressed as %AnSR for tlim120 and tlim140
Number of subjects: 10
Study 9143748 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treatment (90 min/day of isotonic and isokinetic lower extremity exercise training)
Number of subjects: 18
Study 9143748 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 18
Study 7960017 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cardiac index
Number of subjects: 2677
Study 7960017 — intervention group
Group type: EXPERIMENTAL
Intervention: End-systolic wall stress
Number of subjects: 2677
Study 7960017 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased heart rate in men
Number of subjects: 2677
Study 3550148 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 87
Study 3550148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, doxorubicin and cyclophosphamide
Number of subjects: 87
Study 31478704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hurricane scenario (negative)
Number of subjects: 48
Study 31478704 — intervention group
Group type: COMPARATOR
Intervention: Minor storm scenario (neutral)
Number of subjects: 48
Study 29144993 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 66
Study 29144993 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (LTG)
Number of subjects: 66
Study 29144993 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of VPA with LTG
Number of subjects: 66
Study 27566116 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Childhood Mental Health Consultation (ECMHC) through Connecticut's statewide Early Childhood Consultation Partnership (ECCP)
Number of subjects: 176
Study 27566116 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control treatment
Number of subjects: 176
Study 24515352 — intervention group
Group type: EXPERIMENTAL
Intervention: CEPO (carbamylated EPO) 325 µg thrice-weekly
Number of subjects: 36
Study 24515352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23063681 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) 300 U
Number of subjects: 60
Study 23063681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 23063681 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) 100 U
Number of subjects: 60
Study 23063681 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) 500 U
Number of subjects: 60
Study 20647284 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (3 doses at day 1, month 2, and month 6)
Number of subjects: 17622
Study 18580409 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training (ST, n = 72)
Number of subjects: 148
Study 18580409 — intervention group
Group type: COMPARATOR
Intervention: Standard care (CO, n = 76)
Number of subjects: 148
Study 16809804 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g P‐OM3
Number of subjects: 24
Study 16809804 — intervention group
Group type: COMPARATOR
Intervention: 80 mg simvastatin
Number of subjects: 24
Study 14653037 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal technique
Number of subjects: 123
Study 14653037 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein open tension free mesh technique
Number of subjects: 123
Study 10825519 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cervical foraminotomy (FOR)
Number of subjects: 0
Study 10825519 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with fusion (ACDF)
Number of subjects: 0
Study 10825519 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy without fusion (ACD)
Number of subjects: 0
Study 8964410 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (group I)
Number of subjects: 183
Study 8964410 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (group III)
Number of subjects: 183
Study 8964410 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group II)
Number of subjects: 183
Study 8964410 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group IV)
Number of subjects: 183
Study 8964410 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients with marked liver polymorphonuclear infiltrate
Number of subjects: 183
Study 8964410 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients without marked liver polymorphonuclear infiltrate
Number of subjects: 183
Study 8964410 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients with polymorphonuclear counts > 5500/mm3
Number of subjects: 183
Study 8964410 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients with polymorphonuclear counts ≤ 5500/mm3
Number of subjects: 183
Study 8964410 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver polymorphonuclear infiltrate
Number of subjects: 183
Study 8964410 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphonuclear count
Number of subjects: 183
Study 1381822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (M)
Number of subjects: 82
Study 1381822 — intervention group
Group type: COMPARATOR
Intervention: Other antiarrhythmic drugs
Number of subjects: 82
Study 3856903 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal film formulation containing 850 micrograms PGE2
Number of subjects: 0
Study 3856903 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal film
Number of subjects: 0
Study 29278753 — intervention group
Group type: EXPERIMENTAL
Intervention: LRYGB with Intraoperative Endoscopy (IOE)
Number of subjects: 100
Study 29278753 — intervention group
Group type: COMPARATOR
Intervention: LRYGB without Intraoperative Endoscopy (Control)
Number of subjects: 100
Study 26938918 — intervention group
Group type: EXPERIMENTAL
Intervention: SnMP (4.5 mg kg ‐1)
Number of subjects: 213
Study 26938918 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 213
Study 24015968 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical education programme including cognitively demanding (open skill) activities
Number of subjects: 70
Study 24015968 — intervention group
Group type: COMPARATOR
Intervention: Curricular physical education only
Number of subjects: 70
Study 22386222 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional infection control approach implemented during phase 2.
Number of subjects: 16429
Study 22386222 — intervention group
Group type: COMPARATOR
Intervention: Baseline VAP rate during phase 1 (before intervention).
Number of subjects: 16429
Study 20633511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture using root bark of Ulmus davidiana Planch (UDP), administered twice a week for 6 weeks
Number of subjects: 60
Study 20633511 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injections
Number of subjects: 60
Study 18349490 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ physical activity scale (cut-off >14)
Number of subjects: 160
Study 18349490 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ work scale (cut-off >29)
Number of subjects: 160
Study 18349490 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation and exercise
Number of subjects: 160
Study 18349490 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ physical activity scale
Number of subjects: 160
Study 18349490 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ work scale
Number of subjects: 160
Study 18349490 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ work scale (cut-off scores)
Number of subjects: 160
Study 18349490 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 160
Study 18959111 — intervention group
Group type: EXPERIMENTAL
Intervention: Video assisted thoracoscopic anterior correction
Number of subjects: 49
Study 18959111 — intervention group
Group type: COMPARATOR
Intervention: Small incision, thoracotomic anterior correction
Number of subjects: 49
Study 15033843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) with state of the art equipment and standardized growth training session
Number of subjects: 878
Study 15033843 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) without intervention
Number of subjects: 878